MSD INTERNATIONAL GMBH (PUERTO RICO BRANCH) LLC

IO Biotech's therapeutic cancer vaccine Cylembio combined with pembrolizumab achieved a median progression-free survival of 19.4 months versus 11.0 months with pembrolizumab alone in advanced melanoma patients.

IO Biotech's cancer vaccine Cylembio combined with Keytruda showed a 23% relative risk reduction in disease progression or death compared to Keytruda alone, but narrowly missed statistical significance with a p-value of 0.056.

Iovance Biotherapeutics voluntarily withdrew its European Union regulatory filing for Amtagvi due to lack of alignment with the EMA on clinical data supporting the submission.

GSK's anti-TIM-3 monoclonal antibody cobolimab failed to improve overall survival in the Phase III COSTAR trial for advanced non-small cell lung cancer patients previously treated with immunotherapy.

Merck plans to slash $3 billion in costs by the end of 2027 to reinvest in new product launches and drug pipeline development ahead of Keytruda's patent expiration in 2028.

A new comprehensive report analyzes over 200 pipeline drugs from 180+ companies targeting metastatic hormone refractory prostate cancer, highlighting the extensive research efforts in this challenging therapeutic area.

Leveragen, a Boston-based biotech company, has announced a strategic collaboration with newly launched Propeller Bio to advance antibody and protein-based therapeutics development.

Absci Corporation completed a $50 million public offering of 16.67 million shares at $3.00 per share to fund its AI-powered drug discovery programs and internal pipeline development.

Janux Therapeutics showcased its expanded immunotherapy pipeline at R&D Day, highlighting three proprietary platforms: TRACTr, TRACIr, and the novel ARM platform targeting autoimmune diseases.

Omega Funds successfully closed its eighth fund with $647 million in capital commitments, exceeding its $600 million target despite challenging fundraising conditions.